- Home
- HYNE vs XGN Comparison
HYNE vs XGN Comparison
Compare HYNE & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYNE | XGN |
|---|---|---|
| Founded | 2025 | 2002 |
| Country | United States | United States |
| Employees | 61 | N/A |
| Industry | Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.5M | 110.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HYNE | XGN |
|---|---|---|
| Price | $16.36 | $4.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 23.9K | ★ 378.7K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $2.59 |
| 52 Week High | $16.65 | $12.23 |
Technical Indicators
Market Signals| Indicator | HYNE | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 52.70 |
| Support Level | $16.11 | $4.11 |
| Resistance Level | N/A | $5.55 |
| Average True Range (ATR) | 0.16 | 0.40 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 69.09 | 26.05 |
Price Performance
Historical ComparisonAbout HYNE Hoyne Bancorp Inc.
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.